Tag: US8112921015

JERSEY CITY, N.J., Feb. 25, 2021 (GLOBE NEWSWIRE) — SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that Marco Taglietti…

Synergistic combination of Amplity’s proven commercial sales capabilities and SCYNEXIS’ internal medical, marketing, and strategic expertise will maximize Brexafemme’s commercial potential while preserving SCYNEXIS’ global rights to the drugAmplity to …

Synergistic combination of Amplity’s proven commercial sales capabilities and SCYNEXIS’ internal medical, marketing, and strategic expertise will maximize Brexafemme’s commercial potential while preserving SCYNEXIS’ global rights to the drugAmplity to …

Synergistic combination of Amplity’s proven commercial sales capabilities and SCYNEXIS’ internal medical, marketing, and strategic expertise will maximize Brexafemme’s commercial potential while preserving SCYNEXIS’ global rights to the drugAmplity to …

JERSEY CITY, N.J., Dec. 22, 2020 (GLOBE NEWSWIRE) — SCYNEXIS, Inc. (Nasdaq: SCYX) today announced the closing of its previously announced underwritten public offering of common stock, pre-funded warrants and warrants. The shares and warrants were sold at a public offering price of $6.25 per share and accompanying warrants, and the pre-funded warrants were sold […]

JERSEY CITY, N.J., Dec. 17, 2020 (GLOBE NEWSWIRE) — SCYNEXIS, Inc. (Nasdaq:SCYX) today announced the pricing of its underwritten public offering of common stock, pre-funded warrants and warrants. The shares and warrants are being sold at a public offering price of $6.25 per share and accompanying warrants, and the pre-funded warrants are being sold at […]

JERSEY CITY, N.J., Dec. 16, 2020 (GLOBE NEWSWIRE) — SCYNEXIS, Inc. (Nasdaq:SCYX) today announced that it has commenced an underwritten public offering of shares of its common stock and warrants to purchase shares of its common stock, including pre-funded warrants to purchase common stock in lieu of common stock for certain purchasers. All of the […]

JERSEY CITY, N.J., Nov. 24, 2020 (GLOBE NEWSWIRE) — SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the Company’s participation in Piper Sandler’s 32nd Annual Virtual Healthcare Conference. Presentations will be available for registered attendees via the Piper Sandler conference site from November […]

In October, SCYNEXIS submitted a New Drug Application (NDA) for ibrexafungerp for the treatment of vulvovaginal candidiasis (VVC) with expected approval in mid-2021. SCYNEXIS estimates that there are over 15 million antifungal prescriptions written each year for the treatment of VVC. Enrollment is ongoing in the Phase 3 CANDLE study of oral ibrexafungerp for the […]

Three posters highlight the potential for ibrexafungerp use in treating and preventing serious fungal infections JERSEY CITY, N.J., Oct. 21, 2020 (GLOBE NEWSWIRE) — SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that it is presenting three posters on its late-stage, novel broad-spectrum […]